Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
- (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
- Financial results for the quarter ended December 31, 2023:
Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023. - The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
- For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.